The document discusses health and safety challenges in the workplace, including different national systems, economic and demographic changes, new technologies and risks. It emphasizes that safety and health is important for both individuals and businesses. It outlines elements of successful policies for an aging workforce, including integrated frameworks across social, employment, health and safety policies. Key factors include rehabilitation and return to work programs, early intervention, tailored support, and coordination across stakeholders. The document advocates adopting a life course approach to occupational safety and health.
This report documents the collective output of research activities undertaken by the Institute for Employment Studies in response to a request from EU-OSHA to undertake a review of successful OSH benchmarking initiatives. The overarching aim was to review OSH benchmarking schemes that have been set up at sector, Member State or European level in order to assess the benefits that such schemes can deliver, as well as their limitations, and to identify the key factors of and main obstacles to their success.
ICOH 2015 - Seoul. A session at the Asian Policy Forum to examine how the European OSH system works, and how we can look for improvements to address current challenges and new emerging risks.
This PPT gives an overview of the OiRA project, partners, risk assessment tools and the platform that allows to develop those tools.
The presentation was given on 28 November 2013 to the Advisory Committee for Safety and Health at Work in Luxembourg
A Workers’ Survey on Exposure to Cancer Risk Factors in Europe: An Innovative Approach to get Comparable and Reliable Data for Prevention and Policy-making Purposes
Rehabilitation and return to work after cancer – How could instruments and practices support workers and employers? See our editable ppt for non-expert.
This report documents the collective output of research activities undertaken by the Institute for Employment Studies in response to a request from EU-OSHA to undertake a review of successful OSH benchmarking initiatives. The overarching aim was to review OSH benchmarking schemes that have been set up at sector, Member State or European level in order to assess the benefits that such schemes can deliver, as well as their limitations, and to identify the key factors of and main obstacles to their success.
ICOH 2015 - Seoul. A session at the Asian Policy Forum to examine how the European OSH system works, and how we can look for improvements to address current challenges and new emerging risks.
This PPT gives an overview of the OiRA project, partners, risk assessment tools and the platform that allows to develop those tools.
The presentation was given on 28 November 2013 to the Advisory Committee for Safety and Health at Work in Luxembourg
A Workers’ Survey on Exposure to Cancer Risk Factors in Europe: An Innovative Approach to get Comparable and Reliable Data for Prevention and Policy-making Purposes
Rehabilitation and return to work after cancer – How could instruments and practices support workers and employers? See our editable ppt for non-expert.
European Innovation Partnership on Active and Healthy AgeingEIP_AHA
The pilot European Innovation Partnership on Active and Healthy Ageing will pursue a triple win for Europe:
Enabling EU citizens to lead healthy, active and independent lives while ageing;
Improving the sustainability and efficiency of social and health care systems;
Boosting and improving the competitiveness of the markets for innovative products and services, responding to the ageing challenge at both EU and global level, thus creating new opportunities for businesses.
European Innovation Partnership on Active and Healthy AgeingAALForum
A strategy for scaling up successful innovations, a presentation by Loukianos Gatzoulis during the workshop EIP on AHA twinning and upscaling session by Henriette Hansen - AAL Forum 2015
eHealth Summit: "Case Study: The applied research for connected health (ARCH)...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Maria Quinlan, Research Lead Change Work-Package, ARCH.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
eHealth Summit: "ICT Use in Irish General Practices: An Intra-Practice Adopti...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Jane Bourke, Lecturer in Economics, University College Cork.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
Clinical Trial Data Transparency: Explaining Governance for Public Data SharingHealth Data Consortium
Watch the webinar here: http://www.screencast.com/t/0lATKYlJ8
Dr. Chris Boone, then-VP in Avalere’s Evidence Translation and Implementation Practice, discussed clinical trial data transparency and considerations for governance and open data sharing. Clinical trials are extremely valuable as the primary data source for seeking regulatory approval of products. Historically, regulatory agencie have been the sole recipients of clinical trial data, butthere has been a recent push from various stakeholder groups to open access to clinical trial data to non-regulatory researchers as an act of ethical responsibility to patients, a contribution to public health, and a demonstrated commitment to advancing the science. Some of the barriers include developing a sound approach for de-identifying patient data, adopting universal clinical trial data format, and managing the proactive and non-selective access and security of clinical data once collected. Dr. Boone discusses rationales and benefits/risks of clinical trial transparency, responsible use of publicly sharing this data, barriers and legal implications, and reasonable data sharing models.
Discover more health data resources on our website at http://www.healthdataconsortium.org/
Ross McKenna
Portfolio Manager, Health System Infrastructure
Information Strategy and Architecture
National Health Board Business Unit
Ministry of Health
Scaling up innovation in healthcare - A Methodology Framework 2015Marc Lange
This presentation introduce a methodology scaling-up developed by "doers and shapers" internationally known for their expertise in eHealth and digital health
020719 day one accelerator webinar presentationDayOne
Details of the application process for the DayOne accelerator. Applications close July 26th. Details at https://www.dayone.swiss/dayone/accelerator.html
The DayOne accelerator supports healthcare innovators with 50,000CHF in cash and access to Europe's leading healthcare ecosystem. The focus of the program are ventures that can have an impact on the health and wellbeing of children and young people
European Innovation Partnership on Active and Healthy AgeingEIP_AHA
The pilot European Innovation Partnership on Active and Healthy Ageing will pursue a triple win for Europe:
Enabling EU citizens to lead healthy, active and independent lives while ageing;
Improving the sustainability and efficiency of social and health care systems;
Boosting and improving the competitiveness of the markets for innovative products and services, responding to the ageing challenge at both EU and global level, thus creating new opportunities for businesses.
European Innovation Partnership on Active and Healthy AgeingAALForum
A strategy for scaling up successful innovations, a presentation by Loukianos Gatzoulis during the workshop EIP on AHA twinning and upscaling session by Henriette Hansen - AAL Forum 2015
eHealth Summit: "Case Study: The applied research for connected health (ARCH)...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Maria Quinlan, Research Lead Change Work-Package, ARCH.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
eHealth Summit: "ICT Use in Irish General Practices: An Intra-Practice Adopti...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Jane Bourke, Lecturer in Economics, University College Cork.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
Clinical Trial Data Transparency: Explaining Governance for Public Data SharingHealth Data Consortium
Watch the webinar here: http://www.screencast.com/t/0lATKYlJ8
Dr. Chris Boone, then-VP in Avalere’s Evidence Translation and Implementation Practice, discussed clinical trial data transparency and considerations for governance and open data sharing. Clinical trials are extremely valuable as the primary data source for seeking regulatory approval of products. Historically, regulatory agencie have been the sole recipients of clinical trial data, butthere has been a recent push from various stakeholder groups to open access to clinical trial data to non-regulatory researchers as an act of ethical responsibility to patients, a contribution to public health, and a demonstrated commitment to advancing the science. Some of the barriers include developing a sound approach for de-identifying patient data, adopting universal clinical trial data format, and managing the proactive and non-selective access and security of clinical data once collected. Dr. Boone discusses rationales and benefits/risks of clinical trial transparency, responsible use of publicly sharing this data, barriers and legal implications, and reasonable data sharing models.
Discover more health data resources on our website at http://www.healthdataconsortium.org/
Ross McKenna
Portfolio Manager, Health System Infrastructure
Information Strategy and Architecture
National Health Board Business Unit
Ministry of Health
Scaling up innovation in healthcare - A Methodology Framework 2015Marc Lange
This presentation introduce a methodology scaling-up developed by "doers and shapers" internationally known for their expertise in eHealth and digital health
020719 day one accelerator webinar presentationDayOne
Details of the application process for the DayOne accelerator. Applications close July 26th. Details at https://www.dayone.swiss/dayone/accelerator.html
The DayOne accelerator supports healthcare innovators with 50,000CHF in cash and access to Europe's leading healthcare ecosystem. The focus of the program are ventures that can have an impact on the health and wellbeing of children and young people
Food safety along informal pork value chains in Vietnam: Success and challeng...ILRI
Presentation by Fred Unger, Hung Nguyen-Viet, Lucy Lapar, Phuc Pham Duc, Pham Van Hung, Pham Hong Ngan, Max Barot and Delia Grace at the 4th International One Health Congress and 6th Biennial Congress of the International Association for Ecology and Health (One Health EcoHealth 2016), Melbourne, Australia, 3–7 December 2016.
Presentation given by Elke Schneider (EU-OSHA) to the Conference 'Europe at a crossroads. Which way to quality jobs and prosperity?' held under the joint auspices of the European Trade Union Confederation (ETUC) and the European Trade Union Institute (ETUI) held in Brussels on 24-26 September 2014.
This presentation provides an overview of worker participation in the prevention of MSDs and steps that employers can take to actively involve workers in identifying musculoskeletal problems and choosing and implementing the best solutions
This presentation highlights the dangers of prolonged sitting at work, with musculoskeletal pain, cardiovascular disease and cancer being just some of the associated problems.
It outlines who is most at risk and gives handy tips and guidance for employers and workers to keep everyone moving.
This presentation provides an overview of the steps employers can take to support workers with chronic musculoskeletal disorders (MSDs) to manage their condition and continue to work.
Risk assessment is the basis for successful safety and health management, and the key to prevent and manage musculoskeletal disorders. This presentation suggests a straightforward stepwise approach to risk assessment that should work well for most businesses (specially micro and small enterprises).
This presentation provides a general introduction to the prevention and management of musculoskeletal disorders that could be complemented with other presentations or publications in the scope of Campaign 2020-22 Healthy Workplaces Lighten the Load.
The presentation summarizes the final output of a major project that was commissioned to address exposure to biological agents in the workplace and the related health effects. The study included a scientific literature review, interviews with experts, focus group sessions and a stakeholder workshop.
The presentation summarizes the final output of a major project that was commissioned to address exposure to biological agents in the workplace and the related health effects. The study included a scientific literature review, interviews with experts, focus group sessions and a stakeholder workshop.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Toward an active working society: a European global perspective
1. Safety and health at work is everyone’s concern. It’s good for you. It’s good for business.
“Toward an active working society: a
European global perspective”
Dr Christa Sedlatschek
Director
Florence 14 March 2017
Active Ageing: “From research to action oriented policies”
2. 2
www.healthy-workplaces.eu
Some health and safety challenges
28 different OSH systems
Changes in the policy and
regulatory context
Economic and demographic change
Micro and small enterprises
New technologies, new forms of
employment, new ways of working
New and emerging risks
Work related diseases
(psychosocial risks, MSDs, cancer,
etc.)
3. 3
www.healthy-workplaces.eu
Reference to the EU Strategic Framework
challenges or very similar description
Challenge 1: Improving the
implementation record
(particularly by supporting
SMEs and micro enterprises)
Challenge 2: Improving the
prevention of work-related
diseases by tackling existing,
new and emerging risks
Challenge 3: Tackling
demographic change
Austria Austria Austria
Cyprus Cyprus Cyprus[1]
Czech Republic Czech Republic
Denmark Denmark
Estonia Estonia
Finland Finland
France France France
Germany Germany Germany
Ireland Ireland Ireland
Malta Malta
Netherlands Netherlands Netherlands
Poland Poland
Portugal Portugal Portugal
Slovakia Slovakia Slovakia
Spain Spain Spain
Sweden Sweden Sweden
UK UK
4. 4
www.healthy-workplaces.eu
Safer and healthier work at any age
OSH in the context of an ageing workforce
Financed by the European Parliament
Implemented by EU-OSHA 2013-2016
Objectives:
Improving knowledge of existing policies and initiatives addressing
the ageing of the workforce and how they have been implemented in
the MSs and EFTA countries
Providing reliable information and analysis for policy development in
the area of OSH, including rehabilitation and return-to-work policies
Supporting the exchange of good practice at company level
5. 5
www.healthy-workplaces.eu
Integrated policy frameworks
Social policies
Pension reforms:
Raising
retirement age
Limiting access
to early
retirement and
disability
pensions
Employment
Promoting
employment of
older workers
and
employability
Training and
lifelong learning
Targeted support
to older workers
OSH
Sustainable
Work
Working time
arrangements
Work-life
balance
Vocational
rehabilitation
and return-to-
work
Public health
Workplace
Health
Promotion
Work-oriented
medical
rehabilitation
Active and
healthy ageing
Equal
treatment
Prohibition of
discrimination
on grounds of
age and
disability
Maintaining employability & fostering work ability of all workers
Safer and healthier work at any age
Policies to address the challenges of an ageing workforce
Elements of a successful policy
Education
Life-long
learning
Vocational
education
6. 6
www.healthy-workplaces.eu
Elements of a successful policy
Adopting a life course approach to OSH and/or ageing:
•Recognition of the needs of all age groups
Implementing the policy:
•Different types of measures (legal, political, financial,
technical)
•Systematic approach: establishment of objectives and targets,
establishment of action plans, monitoring and evaluation
Engaging stakeholders and raising awareness:
•Developing a common understanding and a common
language (e.g. ‘Sustainable employability’)
•Putting in place platforms for coordination of action and
exchange of experience
National policies to address the challenges of
an ageing workforce
7. 7
www.healthy-workplaces.eu
Rehabilitation and return-to-work systems
•21% of the working population suffer from a long-
standing illness or health problem.
•Total average time spent on sick leave increases with
age.
•Consequences of long-term sickness absence on
workers, employers and society.
•Measures to facilitate rehabilitation and return-to-work to
avoid long-term sickness absence, work disability or
early retirement.
8. 8
www.healthy-workplaces.eu
Rehabilitation and return-to-work systems integrated into
broader policy frameworks for sustainable working lives
Integrated legal
and policy
framework
•Return to work
system inscribed
in legislation and
based on
coordination
across relevant
policy areas.
Inclusive
systems
•Rehabilitation
services and
return-to-work
programmes
target all
employees.
Early
intervention
•Avoiding sickness
absence.
Early workability
assessment.
Maintaining a link
with the
workplace during
the sickness
absence.
Tailored
approach
•Individual
support plan.
Workplace
adaptations.
Vocational and
social
rehabilitation.
Reintegration into
the workplace.
Coordination
mechanisms
•Enhanced role of
employer.
Case
management.
Coordination at
all stages.
Interdisciplinary
teams.
Rehabilitation and return-to-work systems
Elements of a successful system
9. 9
www.healthy-workplaces.eu
Safer and healthier work at any age
Success factors for return to work
Inclusive systems to target all workers with health problems
−Broader scope than disability management
Intervention already at an early stage
Interventions tailored to the workers’ needs
Case manager
Assessment of work capacity, individual support plan
Targeted workplace interventions
Obligations and responsibilities for employers and workers
Coordination at policy level (cross policy), system level and workplace
level (GPs, OSH specialists, rehabilitation service providers, case
manager, employer…)
Financial, technical support to SMEs
Economic drivers before receiving disability or early retirement benefit
Raising awareness about the benefits of RTW
10. 10
www.healthy-workplaces.eu
Safer and healthier work at any age
Success factors at Company Level
Workplace level
• Life course approach, addressing different needs of young and old,
intergenerational interaction.
• Holistic approach, taking into account factors beyond OSH that have an
impact on OSH (e.g. based on work ability concept).
• Workplace Health Promotion.
• Age/diversity sensitive risk assessment, gender issues.
• HR policies supporting OSH management (working time, training).
• Leadership.
• Social dialogue / workers participation.
13. 13
www.healthy-workplaces.eu
Key objectives
Promote sustainable work and healthy ageing from the beginning
of working life
Highlight the importance of prevention throughout working life
Assist employers and workers (including in SMEs) by providing
information and tools for managing OSH in the context of an
ageing workforce
Facilitate information exchange and good practice
https://youtube/9bodWzkkcCU